AUPH Aurinia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AUPH

Price (delayed)

$16.14

Market cap

$2.16B

P/E Ratio

6.84

Dividend/share

N/A

EPS

$2.36

Enterprise value

$2.18B

?
Relative Growth: Rel. Growth: 78
Relative Strength: Rel. Strength: 67
Relative Valuation: Rel. Valuation: 88
Relative Profitability: Rel. Profitability: 99

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the ...

Highlights
AUPH's equity has soared by 80% year-on-year and by 7% since the previous quarter
Aurinia Pharmaceuticals's debt has decreased by 25% YoY and by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.auriniapharma.com
Peers: QURE LXRX

Key stats

What are the main financial stats of AUPH

AUPH stock price

How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
-3.06%
1 week
-5.28%
1 month
1.96%
1 year
22.55%
YTD
1.19%
QTD
-0.34%

Financial performance

How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$321.74M
Gross profit
$291.57M
Operating income
$156.37M
Net income
$314.27M
Gross margin
90.6%
Net margin
97.7%
The operating income has soared by 123% year-on-year and by 3.7% since the previous quarter
The operating margin has soared by 85% YoY
Aurinia Pharmaceuticals's gross profit has increased by 23% YoY and by 3.6% from the previous quarter
The revenue has increased by 21% YoY and by 3.3% from the previous quarter

Price vs fundamentals

How does AUPH's price correlate with its fundamentals

Growth

What is Aurinia Pharmaceuticals's growth rate over time

Valuation

What is Aurinia Pharmaceuticals stock price valuation
AUPH P/E details
P/E
6.84
P/B
3.27
P/S
6.69
EV/EBIT
12.72
EV/EBITDA
11.43
EV/Sales
6.76
The P/E is 2.3% less than the last 4 quarters average of 7.0
AUPH's equity has soared by 80% year-on-year and by 7% since the previous quarter
The price to book (P/B) is 7% lower than the last 4 quarters average of 3.5
The stock's P/S is 37% less than its 5-year quarterly average of 10.7 and 4.4% less than its last 4 quarters average of 7.0
The revenue has increased by 21% YoY and by 3.3% from the previous quarter

Efficiency

How efficient is Aurinia Pharmaceuticals business performance
The company's return on assets has surged by 172% YoY but it fell by 10% QoQ
The ROE has soared by 138% YoY but it has decreased by 12% from the previous quarter
Aurinia Pharmaceuticals's return on sales has surged by 68% YoY
AUPH's ROIC is up by 39% year-on-year but it is down by 7% since the previous quarter

Dividends

What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AUPH.

Financial health

How did Aurinia Pharmaceuticals financials performed over time
Aurinia Pharmaceuticals's total assets has surged by 57% YoY and by 4.2% QoQ
The quick ratio rose by 15% since the previous quarter and by 11% year-on-year
Aurinia Pharmaceuticals's debt is 91% lower than its equity
AUPH's equity has soared by 80% year-on-year and by 7% since the previous quarter
The company's debt to equity has shrunk by 57% YoY and by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.